HARPOON THERAPEUTICS UPDATES INFORMATION FOR ITS PARTICIPATION IN TWO UPCOMING VIRTUAL CONFERENCES

On June 17, 2020 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported new information regarding its participation in two upcoming investor virtual conferences. Gerald McMahon, Ph.D., President and Chief Executive Officer, will now participate in (Press release, Harpoon Therapeutics, JUN 17, 2020, View Source [SID1234561190]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the JMP Securities Hematology & Oncology Forum on Thursday, June 18, 2020 at 3:40 p.m. ET / 12:40 p.m. PT (revised time); and

A presentation (revised format) at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET / 11:30 a.m. PT.
A live audio webcast of the fireside chat and presentation will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.

Incyte Investor Conference Update

On June 17, 2020 Incyte (Nasdaq:INCY) reported that it has updated its presentation time at the following investor conference (Press release, Incyte, JUN 17, 2020, View Source [SID1234561175]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JMP Securities Hematology & Oncology Forum (Virtual) on Thursday, June 18, 2020, now at 3:00 p.m. (EDT).
The presentation at the BMO Prescriptions for Success Healthcare Conference (Virtual) on Tuesday, June 23, 2020 at 1:30 p.m. (EDT) is unchanged.

The presentations for both conferences will be webcast live and can be accessed at Investor.Incyte.com. Replays will be available for 30 days.

Agenus to Present at the Raymond James Virtual Human Health Innovation Conference

On June 17, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies and cancer vaccines, reported that Dr. Jennifer Buell, PhD, President and Chief Operating Officer of Agenus, will present an update on Agenus’ progress and host one-on-one meetings with investors at the Raymond James Virtual Human Health Innovation Conference on June 18, 2020 (Press release, Agenus, JUN 17, 2020, View Source [SID1234561191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Thursday, June 18, 2020

Time: 4:20 pm – 4:450 p.m. ET / Virtual Track 1

Webcast: The presentation will be webcast and can be accessed through the following link: View Source

Spectrum Pharmaceuticals to Present Preclinical ROLONTIS® (eflapegrastim) Same Day Dosing Data at AACR Virtual Annual Meeting II

On June 16, 2020 Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent model (Press release, Spectrum Pharmaceuticals, JUN 16, 2020, View Source [SID1234561126]). The abstract titled "Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy" will be part of the Special Populations, Survivorship, Outcomes, and Supportive Care session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, to be held June 22-24, 2020. Full details of the poster are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Chemotherapy induced neutropenia in rats following administration of eflapegrastim or pegfilgrastim on the same day at three different timepoints and at 24 hours post-chemotherapy
Authors: Yu-Yon Kim., et al.
Session: Special Populations, Survivorship, Outcomes, and Supportive Care
Date and Time: June 22, 2020, 9 a.m. – 6 p.m. EDT
Poster Number: 2044 / 22
Location: Access to the AACR (Free AACR Whitepaper) Virtual Annual Meeting II will be free to everyone. While access will be free, attendees will be required to register to view the meeting. Registration for the meeting is available through the myAACR portal.

Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference

On June 16, 2020 Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that it will release first quarter 2020 results on Tuesday, June 23, 2020 and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments (Press release, Affimed, JUN 16, 2020, View Source [SID1234561142]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 928338 for international callers, and reference conference ID 8594214 approximately 15 minutes prior to the call.

To access the live audio webcast of the conference call please visit the "Investors" section of company’s website at View Source A replay of the call will be archived on the Affimed website for 30 days after the call.

BMO Conference Participation
Affimed also announced that its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the 2020 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 23rd, at 1:30 p.m. EDT.
A live webcast of the fireside chat will be available on the "Investors" section of the company’s website at View Source A replay of the fireside chat will be archived on the Affimed website for 30 days following the event.